|
Tavist-dDrug - Tavist-d The trade name of the product as shown on the labeling.
Dosage -
TABLET, EXTENDED RELEASE; ORAL
Active Ingredient(s) -
Clemastine Fumarate; Phenylpropanolamine Hydrochloride
Strength -
1.34MG;75MG
Applicant -
NOVARTIS
New Drug Application (NDA) Number -
018298
Product Number -
002
Therapeutic Equivalence (TE) Code -
Approval Date -
Aug 21, 1992
Reference Listed Drug (RLD) -
No
Type -
DISCN
Applicant Full Name -
Novartis Pharmaceuticals Corp
Tavist-d
Tavist-1 1.34mg Tablet; Oral
Tavist-d 1.34mg;75mg Tablet, Extended Release; Oral Clemastine Fumarate 1.34mg Tablet; Oral Clemastine Fumarate 2.68mg Tablet; Oral Clemastine Fumarate 1.34mg Tablet; Oral Clemastine Fumarate 1.34mg Tablet; Oral Clemastine Fumarate 2.68mg Tablet; Oral Tavist 2.68mg Tablet; Oral Tavist-1 1.34mg Tablet; Oral Tavist-1 1.34mg Tablet; Oral NewDrugInformation |